<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03010124</url>
  </required_header>
  <id_info>
    <org_study_id>2015-A01183-46</org_study_id>
    <secondary_id>2015/2290</secondary_id>
    <nct_id>NCT03010124</nct_id>
  </id_info>
  <brief_title>Prognostic and Predictive Biomarkers in Ovarian Cancers</brief_title>
  <acronym>OvBIOMark</acronym>
  <official_title>Prognostic and Predictive Biomarkers in Ovarian Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gustave Roussy, Cancer Campus, Grand Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators therefore propose to conduct a biological study of prospectively collected
      patient tumour samples, ascites, blood and other residual samples (feces, urine, cervical
      smear) throughout the disease course where markers (at diagnosis and their change with
      treatment) will be correlated to outcome in order to investigate how genetic diversity in OC
      prior to treatment and adaptation following treatment contribute to chemotherapy resistance.
      In addition freshly collected ascitic samples (and tumour samples) will be subjected to ex
      vivo DNA repair functional assays and isolated in primary culture (and established as
      xenografts) for target validation experiments.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 26, 2016</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Correlation of baseline biomarkers with PFS will occur at 12 months following last patient inclusion</time_frame>
    <description>up to 12 months</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Patients with ovarian cancer</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <arm_group_label>Patients with ovarian cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. New patient with a diagnosis of OC, or

          2. Previously treated patient with frozen or formalin fixed paraffin embedded primary
             tumour sample available that can be retrieved by the center presenting with
             progressive disease, and consenting to CT guided biopsy of relapsed disease, or

          3. Previously treated patient with frozen or formalin fixed paraffin embedded primary
             tumour sample available that can be retrieved by the center scheduled for surgery for
             relapsed disease.

          4. Signed informed consent

          5. Age â‰¥ 18

          6. Patient affiliated to a social security regimen or beneficiary of the same

        Exclusion Criteria:

          1. Patients who do not fit the inclusion criteria and those who refuse an antitumoral
             treatment;

          2. Coagulation abnormalities that contra-indicates the biopsy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alexandra LEARY, MD</last_name>
    <phone>0142114389</phone>
    <phone_ext>+33</phone_ext>
    <email>alexandra.leary@gustaveroussy.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ariane DUNANT</last_name>
    <phone>0142114211</phone>
    <phone_ext>+33</phone_ext>
    <email>ariane.dunant@gustaveroussy.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <state>Val De Marne</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandra LEARY, MD</last_name>
      <phone>0142114389</phone>
      <phone_ext>+33</phone_ext>
      <email>alexandra.leary@gustaveroussy.fr</email>
    </contact>
    <contact_backup>
      <last_name>Ariane DUNANT</last_name>
      <phone>0142114211</phone>
      <phone_ext>+33</phone_ext>
      <email>ariane.dunant@gustaveroussy.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>December 13, 2016</study_first_submitted>
  <study_first_submitted_qc>January 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2017</study_first_posted>
  <last_update_submitted>February 14, 2020</last_update_submitted>
  <last_update_submitted_qc>February 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

